

Your Tailored Approach to Emerging Markets

Newsletter VI



Covid-19 pandemic has spread with over 9.4 Mn cases worldwide as of 24th June 2020.

Although there is still a lot of research going on globally both, a vaccine and medication, there is still a huge demand of syringes stemming from the fact that other supplements and medication are given to

Major Suppliers of Global Syringe market include:

- B. Braun Melsungen AG (Germany)
- Becton Dickinson and Co. (USA)
- CODAN Medizinische Gerate GmbH & Co. KG (Germany)
- Gerresheimer AG (Germany)
- Henke-Sass Wolf GmbH (Germany)
- Medtronic Plc (USA, Ireland)
- NIPRO CORPORATION (Japan)
- Novo Nordisk A/S (Denmark)
- Retractable Technologies Inc. (USA)
- Terumo Corp. (Japan)
- Thermo Fisher Scientific Inc. (USA)
- Smiths Medical, Inc. (USA)
- Star Syringe Ltd (UK)
- Unilife Corporation (USA)

USA, China, France, Germany, Switzerland, Netherlands, Belgium, Italy, Singapore, and UK were among the top 10 exporting countries in 2019.


Because of Covid-19 spread, there are many production and transportation restrictions across the globe.

To combat this public health emergency, many local companies are helping with increased syringe production.


In this critical time, many fraudulent and criminal activities are detected and reported in various countries. Maximum proportion of which is cyber scams claiming to have standard medical devices and PPE, and sub-standard product sold with false certification of standards.

In both the cases, buyer can be protected with knowledge of proper standards required for that product, its procedure, and authorised entities to verify and approve that standard of that product.

EU Regulation




According to European Commission medical device classification, Syringe are classified as Class IIa medical device under Medical Device Directive (MDD) 93/42/EEC which is replaced by Medical Device Regulation (EU) 2017/745 (MDR).



Regulation (EU) 2017/745 of 5 May 2017 on Medical Devices and Accessories, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and replacing Council Directives 90/385/EEC and 93/42/EEC includes 3 years transitional period, which was due to be fully applicable in EU Member States from 26 May 2020. But due to Covid-19 outbreak, the European Commission has extended the transition period by one year, till 26 May 2021.

Manufacturer or Supplier can opt for either MDD 93/42/EEC or Regulation (EU) 2017/425 (if fully comply) to place medical device on the market during this transition period.

Routes for CE Mark:




Manufacturer or supplier needs to route through complete process (as explained above) for certified CE Mark with Authorized Notified Body.

Notified Bodies for Regulation (EU) 2017/745:

Body type	Name	Country
NB 0086	BSI Assurance UK Ltd	UK
NB 2797	BSI Group The Netherlands B.V.	Netherlands
NB 2409	CE Certiso Orvos- és Kórháztechnikai Ellenőrző és Tanúsító Kft.	Hungary
NB 1912	DARE!! Services B.V.	Netherlands
NB 0344	DEKRA Certification B.V.	Netherlands
NB 0124	DEKRA Certification GmbH	Germany
NB 2460	DNV GL Presafe AS	Norway
NB 0051	IMQ ISTITUTO ITALIANO DEL MARCHIO DI QUALITÀ S.P.A.	Italy
NB 2862	Intertek Medical Notified Body AB	Sweden
NB 0483	MDC MEDICAL DEVICE CERTIFICATION GMBH	Germany
NB 0482	MEDCERT ZERTIFIZIERUNGS- UND PRÜFUNGSGESELLSCHAFT FÜR DIE MEDIZIN GMBH	Germany
NB 0050	National Standards Authority of Ireland (NSAI)	Ireland
NB 0197	TÜV Rheinland LGA Products GmbH	Germany
NB 0123	TÜV SÜD Product Service GmbH Zertifizierstellen	Germany

Notified Bodies for MDD 93/42/EEC are listed on official European Commission website.

FDA Standards



List of different types of Syringes with Regulation Number, classified by FDA:

Duaduat			Dogulation
Product Code	Device	Device Class	Regulation Number
DQF	Actuator, Syringe, Injector Type	2	870.1670
DXT	Injector And Syringe, Angiographic	2	870.1650
ECB	Unit, Syringe, Air And/Or Water	1	872.4565
EIB	Syringe, Irrigating (Dental)	1	872.4565
EIC	Syringe, Periodontic, Endodontic, Irrigating	1	872.4565
EID	Syringe, Restorative And Impression Material	1	872.4565
EJI	Syringe, Cartridge	2	872.6770
FIH	Pump, Infusion Or Syringe, Extra-Luminal	2	876.5820
FMF	Syringe, Piston	2	880.5860
IQG	Adaptor, Holder, Syringe	1	890.5050
IWR	Holder, Syringe, Lead	1	892.6500
KCP	Syringe, Ent	1	874.5220
KYZ	Syringe, Irrigating (Non Dental)	1	880.6960
KZH	Introducer, Syringe Needle	2	880.6920
MAV	Syringe, Balloon Inflation	2	870.1650
MEG	Syringe, Antistick	2	880.5860
NKN	Syringe, Piston, Reprocessed	2	880.5860
NKT	Injector And Syringe, Angiographic, Reprocessed	2	870.1650
NKU	Injector And Syringe, Angiographic, Balloon Inflation, Reprocessed	2	870.1650
NKW	Actuator, Syringe, For Injector, Reprocessed	2	870.1670
PBU	Bone Void Filler, Syringe	Not Classified	
PGO	Anti-Stick Glass Syringe	Not Classified	
PNR	Enteral Syringes With Enteral Specific Connectors	2	876.5980
PQX	Epinephrine Syringe	2	880.5860
PTM	Syringe, Balloon Inflation, Exempt	2	870.1650
PUR	Vacuum Syringe	2	880.5860

QBL	Piston Syringe Lever	2	880.5860
QDM	Midazolam Syringe	2	880.5860
QEH	Piston Syringe With Neuraxial Connector - Epidural And Peripheral Delivery	2	880.5860

Manufacturer/Supplier must meet the requirement of 510(k) submission. Before marketing a device, each submitter must receive an order, in the form of a letter, from FDA which finds the device to be Substantially Equivalent (SE) and states that the device can be marketed in the US. This order "clears" the device from commercial distribution.

The 510(k) Submission Process

A 510(k) submission must be submitted in an electronic format (eCopy), should be sent to CDRH's or CBER's Document Control Center (DCC), which is available on eCopy Program for Medical Device Submissions



If the proper user fee has not been paid and/or a valid eCopy has not been provided, then the DCC will email a Hold Letter to the 510(k) submitter, usually within 7 days of receipt of the 510(k). Submitter needs to resolve it within 180 days. If not resolved, it will be considered as withdrawn and has to submit new 510(k) FDA marketing clearance

After the Acknowledgement Letter is sent, the DCC routes the 510(k) to the appropriate ODE or OIR Division

Within 15 days of the receipt of the submission, the submitter will receive an electronic notification of the Acceptance Review result, which will: Identify name & contact information of FDA Lead Reviewer and Indicate the status

If the Lead Reviewer sends an AI (Additional Information) Request, the submission is placed on hold. The submitter must submit the response, with a valid eCopy, to the DCC within 180 calendar days of the date of the AI Request; including the submitter's name; 510(k) number; identify the submission as Additional Information (AI) to the 510(k); date of FDA's request for AI and provide the requested information in an organized manner

When a decision is made, FDA will issue the decision letter to the submitter by email to the email address provided in the 510(k) cover letter. A 510(k) that receives an SE decision is considered "cleared." And submitter will be added in the 510(k) database, which is updated weekly.

FDA Process Timeliness

By Day 1

•FDA receives 510(k) submission

By Day 7

- FDA Sends
 Acknowledgement
 Letter OR
- •FDA Sends Hold Letter if unresolved issue with User Fee

By Day 15

- •FDA conducts
 Acceptance
 Review
- •FDA informs submitter if 510(k) is accepted for Substantive Review or placed on RTA

By Day 60

- FDA conductSubstantive Review
- FDA communicates via Substantive Interaction to inform the submitter that the FDA will either proceed with Interactive Review or that the 510(k) will be placed on hold and Additional Information is

By Day 90

•FDA sends final MDUFA (Medical Device User Fee Amendments) Decision on By Day 100

•If MDUFA
Decision is not
reached by Day
100, FDA
provides missed
MDUFA
Decision
communication
that identifies
outstanding
review issues

Compliance Check

FDA Compliance:

- FDA approved or cleared suppliers are listed on official FDA website under Establishment Registration & Device Listing section and are weekly updated.
- Suppliers authorized under EUA are listed and updated on EUA page for particular product category on FDA website.
- Third Party Reviewers are mentioned and updated on FDA website along with the product category they are permitted to review by FDA.

CE mark Compliance:

- There is no central database for CE marks and Notified bodies certificate. Only Notified body who issued the certificate can validate it.
- Notified Bodies are listed under each legislation on official European Commission website.
- Not each Notified Bodies can certify any product. Notified Bodies listed under particular legislation are authorized to certify the range of products lying under that legislation only.

Contact Us



EUROPEAN Offices

Dragon Sourcing Paris

57 Rue de Fontenay 92140 Clamart France Tel::+33 (0)7 50 65 09 23

Email: bonjour@dragonsourcing.com

Dragon Sourcing Spain

Carrer de Biada 5, Bajos., 08012 Barcelona, Spain London, W1U 6PZ, UK Tel:+ 34 689 87 09 02

Email: hello@dragonsourcing.com

Dragon Sourcing Russia

Aleksandri Monahovoi St 98, block 1

Moscow, 108801, Russia

Email: hello@dragonsourcing.com

Dragon Sourcing Turkey

Yuzuncu Yil Mah. Prof Erdal Inonu Cad.. No 10 Dalgic Sitesi B Blok Daire 30 Nilufer Bursa, Turkey

Tel: +90 505 506 86 76

Email: merhaba@dragonsourcing.com

Dragon Sourcing South Africa

94 Princess Avenue, Benoni 1500, Gauteng Province, South Africa

Tel: +27 61 128 1949

Email: contact.hello@dragonsourcing.com

LATIN AMERICAN Offices

Dragon Sourcing Brazil

Rua Funchal, 538, 2 andar 04551-060, Vila Olímpia, São Paulo, Brazil Tel:+55 11 9 9595 0405

Email: ola@dragonsourcing.com

Dragon Sourcing Mexico

PROLONGACION VASCO DE QUIROGA # 4800, Tower II Office 102 Floor 1 SANTA FE CUAJIMALPA, MEXICO CITY,

Phone +52 312 1217217

Email: hello@dragonsourcing.com

ASIAN Offices

Dragon Sourcing Shanghai

Suite 1502-1503, Jin Tian Di International Mansions 998. Renmin Road – Shanghai, 200021, P.R.China

Tel: +86 21 61 41 39 55 Fax: +86 21 61 41 39 66

Email: contact.asia@dragonsourcing.com

Dragon Sourcing Hong Kong

10/F Guangdong Investment Tower,148 Connaught Road Central, Hong Kong

Tel:+852 91 80 40 57 Fax: +852 25 80 24 26

Email: contact.asia@dragonsourcing.com

Dragon Sourcing Vietnam

Room A1.03, Hoang Anh River View 37 Nguyen Van Huong Street, Thao Dien Ward,, District 2, HCM City, Vietnam

Tel:+84 28 6685 3589

Email: hello@dragonsourcing.com

Dragon Sourcing Saudi Arabia

Thiqa Bldg. 2nd Flr., Othman Ibn Affan Road (Exit 7 King Abdullah Road Al-Waha District

Riyadh, Kingdom of Saudi Arabia

Tel: +966 11 810 2252

Email: hello@dragonsourcing.com

Dragon Sourcing India

Suite 1502, Sorrento, Veera Desai Road,

Andheri West, Mumbai - 400053

India

Email: contact.india@dragonsourcing.com

NORTH AMERICAN Office

Dragon Sourcing Houston

4532 Plantation Colony Dr Missouri City, TX 77459 Phone: 832- 406-0281

Email: hello@dragonsourcing.com

Disclaimer

The Analysis and Statements in this Report represent the considered views of Dragon Sourcing Ltd (DSL). The Report includes 'forward looking statements' and opinions based on the analyst's current analysis and judgment of the Industry. Although DSL believes the outcomes expressed in such 'forward looking' statements are based on reasonable assumptions, such statements are not a guarantee of future performance and actual results or developments may differ materially from those in forward- looking statements. Factors that could cause actual results to differ materially from those in forward- looking statements include the general economic, environmental, market, business, or government conditions. While DSL has made every reasonable effort to ensure the veracity of the information presented, it cannot expressly guarantee the accuracy and reliability of the estimates, forecasts, and conclusions. Information presented in this report is simplified and need not be the exact, accurate process as defined by FDA and/or European Commission. Suppliers and others interested in obtaining FDA and/or CE approvals and clearances should follow instructions and information available on the FDA and/or European Commission and EU Members websites only.

No part of this report may be distributed, copied, or reused without prior written permission from Dragon Sourcing Ltd. Please contact the author should you have any questions.



Komal Patel

Email: komal.patel@dragonsourcing.com

© 2020 Dragon Sourcing. All rights reserved.

www.dragonsourcing.com

